Skip to main content

Table 2 Patients’ characteristics at virological failure

From: Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

Patient ID Previous resistance mutations Nadir CD4+ (cells/μL) HIV-RNA zenith (copies/mL) CD4 + (cells/μL) at baseline HIV-RNA at baseline 3rd drug CD4 + (cells/μL) at failure HIV-RNA (copies/mL) at failure History of NRTI failure History of NNRTI failure History of PI failure NRTI mutations NNRTI mutations PI mutations InSTI mutations
1412 N/A 258 500.000 675 Undetectable RPV 691 69 Yes No Yes None None None None
1428 N/A 200 1.400.000 700 Residual viremia RAL 356 11.236 Yes Yes Yes M41 L, M184 V, L210 W, T215Y K103 N, V108I None N155H
2718 N/A 245 350.000 922 Undetectable RPV 660 27.823 No No No M41 L, K65R, D67N, M184 V Y181V M46I None
4418 N/A 229 751.000 674 Residual viremia RPV 578 4.737 No No No A62V, K65R, M184 V V106I, E138K, H221Y None N/A
5443 N/A 113 1.978.100 694 Residual viremia RPV 648 367 No No No N/A N/A N/A N/A
5799 N/A 324 70.000 653 Residual viremia RAL 594 138 Yes No No N/A N/A N/A None
5967 N/A 182 78,674 1166 Undetectable RPV 1083 326 No No No D67N, K70R, M184 V, T215I, K219E L100I, K103 N, V179 T None None
6264 N/A 374 570 904 Residual viremia RAL 697 216 No No No N/A N/A N/A N/A
7165 None 488 1.492.000 995 Undetectable RPV 1224 181 No No No N/A N/A N/A N/A
8270 None 108 374.400 444 Undetectable RPV 598 89 Yes No Yes N/A N/A N/A N/A
9037 None 283 46.291 921 Undetectable RPV 1067 104 No No No N/A N/A N/A N/A
9827 N/A 95 279 113 Residual viremia EVG/COBI 174 52 No No No N/A N/A N/A None
  1. EVG/COBI Elvitegravir/cobicistat, InSTI Integrase strand transfer inhibitor, N/A Not available, NNRTI Non-nucleoside reverse transcriptase inhibitor, NRTIs Nucleoside reverse transcriptase inhibitors, PI Protease inhibitor, RAL Raltegravir, RPV Rilpivirine